You can buy or sell Erytech Pharma and other stocks, options, ETFs, and crypto commission-free!
Erytech Pharma S.A. American Depositary Shares, also called Erytech Pharma, is a biopharmaceutical company, which develops medical products. Read More It engages in developing and producing therapeutic products for cancer and orphan diseases. The company was founded by Pierre-Olivier Goineau and Yann Godfrin on November 22, 2004 and is headquartered in Lyon, France.
52 Week High
52 Week Low
Seeking AlphaMay 13
Erytech Pharma on go with late-stage study of eryaspase in pancreatic cancer
The FDA has signed off on ERYTECH Pharma's (NASDAQ:ERYP) IND for a Phase 3 clinical trial evaluating lead candidate eryaspase, an enzyme called L-asparaginase encapsulated in donor-derived red blood cells, in second-line pancreatic cancer.
Seeking AlphaMay 13
ERYTECH Pharma S.A. CEO Gil Beyen on Q1 2019 Results - Earnings Call Transcript
ERYTECH Pharma S.A. (NASDAQ:ERYP) Q1 2019 Results Earnings Conference Call May 7, 2019 8:30 AM ET Company Participants Gil Beyen - Chief Executive Officer Eric Soyer - Chief Financial Officer and Chief Operating Officer Iman El Hariry - Chief Medical Officer Conference Call Participants Boris Peaker - Cowen and Company Anastasia Karpova - Kempen Philippa Gardner - Jefferies Operator Thank you, Michelle. Good morning. I'm in Boston right now. So, people on the side. And good afternoon in Europe. We...
Markets InsiderMay 6
ERYTECH Provides Business Update and Reports Financial Results for First Quarter 2019
TRYbeCA1, pivotal Phase 3 trial for eryaspase in second line pancreatic cancer, actively enrolling patients Construction of new manufacturing site in Princeton and extension of Lyon facility completed Cash position of €110.5 million ($124 million) at the end of March – Cash utilization guidance confirmed LYON, France, May 06, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP),a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug ...
Expected Aug 12, Pre-Market